News - Brightlands Venture Partners

Hy2Care® received FDA IDE approval to launch U.S. clinical trial for cartilage repair implant

April 17, 2025

Grassa Raises EUR 3.6 Million; Grass Protein Consumption by Humans Draws Closer

March 19, 2025

Vivalyx Backed by EIC Accelerator with up to €8.5M to Advance Organ Revitalization Technology

February 20, 2025

Pierpaolo Padula joins Health Team BVP

January 20, 2025

Matisse Pharmaceuticals receives BfArM approval to study a prolonged infusion of M6229

October 24, 2024

Bio-Engineering scale-up Qorium unveils cultivated leather breakthrough, marking major progress toward commercialization

October 23, 2024

Matisse Pharmaceuticals appoints Prof. Carolyn Calfee to the Scientific Board

October 22, 2024

PL BioScience closes € 7.8 million Series A Financing

August 08, 2024

BVP 2023 Impact Report Now Available!

June 27, 2024

Vivalyx secures seed financing to improve donor organ quality

April 30, 2024

Funding for TripleMed to achieve CE marking

March 21, 2024

Matisse Pharmaceuticals meets primary objectives in study with M6229 in critically ill sepsis patients.

January 30, 2024

More information

If you have any questions or want to know more about us
Contact us